Print full article

Stereotactic radiation may offer better outcomes in nine cancers

PetCure Oncology says pets with brain, nasal, and other tumor types are surviving longer

Suggested Veterinary Products

New data suggests a specific advanced radiation treatment protocol is leading to better survival outcomes than other therapy options for at least nine tumor types.

That’s according to PetCure Oncology, which presented its findings at the recent Veterinary Cancer Society Annual Conference (VCS) in Houston, Tex.

The pet cancer care provider says nine of the 11 tumor types it studied showed increased median survival time relative to the current body of peer-reviewed published literature for pets treated with stereotactic radiation/stereotactic radiation therapy (SRS/SRT), an advanced form of radiation therapy used in human medicine.

The list of tumor types includes brain, nasal, osteosarcoma (bone tumors), mast cell, and melanoma.

“We have now treated more than 3,000 pets on-protocol with radiation therapy, including more than 2,200 with stereotactic radiation,” says PetCure’s chief medical officer, Neal Mauldin, DVM, DACVIM (internal medicine and oncology), DACVR (radiation oncology).

“The good news is that many of them are still alive and thriving, so the data is still maturing. But objective analysis of the preliminary data at this point suggests stereotactic radiation can be considered a standard of care for the treatment of many tumor types, much like it already is in human cancer treatment. This research is the least PetCure Oncology can do for the many pet owners suffering with a cancer diagnosis.”

PetCure says the released data is a preliminary analysis. Formal publication through peer-reviewed channels is scheduled for next year and beyond as each segment of the data matures.


Leave a Comment



Sign-up for your account with Veterinary Practice News. Your account gives you unlimited free access to our Newsletter Archives and our Digital Editions of Veterinary Practice News.
Please check the box below to confirm you would like to be added to Kenilworth Media’s various e-mail communications (includes e-newsletters, a survey now and then, and offers to the veterinarian industry*).

Leave this empty:

*We do not sell your e-mail address to 3rd parties, we simply forward their offers to you. Of course, you always have the right to unsubscribe from any communications you receive from us, should you change your mind in the future.